This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug delivery			
Cancer vaccine adjuvant for the brain	<p>A study in mice suggests that FMS-related tyrosine kinase 3 ligand (FLT3LG; FLT3L) could be useful for stimulating an immune response against brain tumors. In mice with brain tumors, vector-based expression of Flt3l in brain tissue increased dendritic cell infiltration, inflammation and immune response against a model antigen compared with those in mice given empty vector. Next steps include a Phase I clinical trial of the approach in glioblastoma multiforme.</p> <p>Celldex Therapeutics Inc. has FLT3L in preclinical development as a dendritic cell-mobilizing reagent for as yet undetermined indications.</p> <p>SciBX 3(31); doi:10.1038/scibx.2010.966 Published online Aug. 12, 2010</p>	Patent pending; available for licensing	<p>Larocque, D. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online July 26, 2010; doi:10.1073/pnas.0913496107 Contact: Pedro R. Lowenstein, Cedars-Sinai Medical Center, Los Angeles, Calif. e-mail: lowensteinp@cshs.org</p>